By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Oxford BioTherapeutics 

94a Milton Park

Abingdon  Oxon  OX14 4RY  United Kingdom
Phone: 44-0-1235-861770 Fax: 44-0-1235-861771



Company News
Boehringer Ingelheim Exercises Option On Second Oncology Target Using Oxford BioTherapeutics' OGAP System 4/18/2016 9:11:21 AM
Oxford BioTherapeutics Licenses Nerviano Medical Sciences (NervianoMS)' Drug-Linker Technology To Develop Novel Antibody Drug Conjugates 4/4/2016 6:28:40 AM
Invenra And Oxford BioTherapeutics Enter Collaboration To Discover Novel Therapeutic Antibodies Targeting Cancer 6/25/2015 6:22:47 AM
Oxford BioTherapeutics Grants An Exclusive License To Boehringer Ingelheim For Development And Commercialization Of Antibody Products To An Oncology Target 1/14/2015 7:26:44 AM
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014 5:41:30 AM
Oxford BioTherapeutics And Berlin-Chemie/Menarini Group Progress Antibody-Drug Conjugate As Second Clinical Development Candidate In $1 Billion Oncology Investment Alliance 10/2/2014 8:58:52 AM
Oxford BioTherapeutics Appoints Dr. Eugen Leo As Head Of Clinical Development 7/8/2014 10:44:07 AM
Oxford BioTherapeutics Appoints Dr Keith E Wilson As Chief Scientific Officer 6/18/2014 9:26:37 AM
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD To Its Board Of Directors 1/15/2014 8:00:19 AM
Oxford BioTherapeutics And Menarini Group Progress Enhanced Antibody For Acute Myeloid Leukemia As First Clinical Development Candidate In $1 Billion Oncology Investment Alliance 12/9/2013 7:57:38 AM